Contribute Try STAT+ Today

For biotech companies, 2020 could have been a lot worse than it was, all things considered. More than most other businesses, small, early-stage biotech startups were better placed to dodge some of the pandemic’s immediate consequences.

When state governments issued stay-at-home orders, many declared that biotech scientists and technicians were essential workers and could continue to go into their labs. Companies that had yet to start clinical trials didn’t need to pause them. And dozens of biotech companies that went public in 2020 found surprisingly welcoming markets for their stocks.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.